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Aims. To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart [FA]) vs insulin aspart (IAsp) in continuous subcutaneous insulin infusion (CSII) in participants with type 1 diabetes. 
Materials and methods. Double-blind, treat-to-target, randomized, 16-week trial investigating CSII treatment with FA (n = 236) or IAsp (n = 236). All available information regardless of treatment discontinuation was used for the evaluation of effect. 
Results. FA was non-inferior to IAsp regarding the change from baseline in HbA1c (primary endpoint). Mean HbA1c changed from 7.5% (baseline) to 7.4% (FA) and 7.3% (IAsp) with an estimated treatment difference (ETD) 0.09% [95%CI 0.01;0.17] (1.0 mmol/mol [95%CI 0.14;1.87]; P < 0.001 for non-inferiority [0.4% margin], P < 0.02 for statistical significance in favour of IAsp). FA was superior to IAsp in change from baseline in 1-h postprandial glucose (PPG) increment after a meal test (ETD [95%CI] −0.91 mmol/L [–1.43;–0.39]; –16.4 mg/dL [–25.7;–7.0]; P = 0.001) with statistically significant reductions also at 30-min and 2-h. The improvement in PPG was reflected in the change from baseline in 1-h interstitial glucose increment after all meals (ETD [95%CI] −0.21 mmol/L [−0.31;−0.11]; −7.69 mg/dL [−12.15;−3.23]). There was no statistically significant difference in the overall rate of severe or blood glucose-confirmed hypoglycaemia (estimated rate ratio [95%CI] 1.00 [0.85;1.16]). A numerical imbalance in severe hypoglycaemic episodes between FA and IAsp was seen in the treatment (21 vs 7) and 4-week run-in periods (4 vs 0).
Conclusions. FA provides an effective and safe option for CSII treatment in type 1 diabetes.




Insulin pump therapy (or continuous subcutaneous insulin infusion [CSII]) in people with type 1 diabetes (T1D) presents advantages over multiple daily insulin injection (MDI) regimens. These include improved glycaemic control and a reduced rate of hypoglycaemic episodes. ADDIN EN.CITE 1,2 However, real-world data show that despite using CSII with or without continuous monitoring devices, only 30% of adults with T1D achieve HbA1c of <7.0%. ADDIN EN.CITE 3 In addition to better insulin delivery and monitoring technologies, there is also a need to develop insulins with pharmacological and glucose-lowering profiles that more closely resemble physiological insulin action. To this end, ultra-fast-acting insulins, such as fast-acting insulin aspart (faster aspart), ADDIN EN.CITE 4 BioChaperone lispro,5 and treprostinil lispro6 that target postprandial glucose (PPG) excursions, are under study or in development for use with MDI and CSII regimens; inhaled insulin is also under study as an alternative approach.7 PPG is an important component of improving overall glycaemic control.

Faster aspart is conventional insulin aspart (IAsp) in a new formulation in which two excipients, niacinamide and L-arginine, have been added. ADDIN EN.CITE 4 A pooled analysis in participants with T1D demonstrated an earlier onset of appearance, a higher early insulin exposure and a greater early glucose-lowering effect with faster aspart vs IAsp, when both were administered by subcutaneous injection. ADDIN EN.CITE 4 More pronounced clinical pharmacological improvements and a greater glucose-lowering effect were demonstrated in people with T1D using CSII. ADDIN EN.CITE 8,9 

In people with T1D, faster aspart was non-inferior (0.4% margin) to mealtime IAsp when combined with insulin detemir after 26 weeks of treatment regarding change in HbA1c. In addition, faster aspart was associated with a significantly greater reduction in HbA1c and superior 2-h PPG increment (meal test), with no difference in the incidence of overall severe or blood glucose (BG)-confirmed hypoglycaemia. ADDIN EN.CITE 10 Faster aspart was compared with IAsp during CSII therapy in a randomized study of 37 participants with T1D. There were no detected microscopically confirmed infusion-set occlusions in either treatment arm over a 6-week period.11 





In this double-blind, randomized, multicentre, parallel-group, treat-to-target trial with a 4-week run-in and 16-week treatment period (Clinicaltrials.gov: NCT02825251), faster aspart was compared with IAsp, both administered via CSII, in adults with T1D (Supplementary Figure 1). The trial was conducted at 92 sites in nine countries (Belgium, Canada, France, Germany, the Netherlands, Russian Federation, Slovenia, UK, USA). A list of study sites and investigators is included in the Supplementary Appendix. The trial was conducted according to the Declaration of Helsinki Amended 2013 and ICH Good Clinical Practice (1996). All patients provided written informed consent.

Participants
Adults (≥18 years) with T1D (diagnosed clinically for ≥12 months) were eligible if they were using the same insulin pump (MiniMed530G, Paradigm Veo, Paradigm Revel, or Paradigm; Medtronic Inc, Minneapolis, MN, USA) for CSII therapy with a rapid-acting insulin analogue for ≥6 months prior to screening, and they were willing to stay on the same pump model throughout the trial. Further eligibility criteria were HbA1c 7.0–9.0% (53–75 mmol/mol) and BMI ≤35 kg/m2. Full inclusion and exclusion criteria are listed in the Supplementary Appendix.

Procedures
During the 4-week run-in period, participants remained on their pre-trial insulin, and basal pump rates and bolus dose calculator settings were not adjusted unless for safety reasons. At randomization, participants switched from pre-trial insulin to faster aspart or IAsp (both 100 U/mL), both double-blind, on a unit-for-unit basis, keeping current pump parameters the same. During the 16-week treatment period, the fasting and pre-prandial BG glycaemic target was 4.0–6.0 mmol/L (71–108 mg/dL). Participants’ performed basal rate checks based on frequent measurements of self-measured blood glucose (SMBG) values and following instructions from the investigator. Basal rates were adjusted to ensure that BG was kept in a stable range (within 2 mmol/L [35 mg/dL]) while in a fasting state. Mealtime insulin (initiated 0–2 min before a meal) was titrated based on carbohydrate counting using a bolus dose calculator according to usual practice. Basal rates, as well as insulin:carbohydrate ratios, insulin sensitivity factors, and active insulin time, were adjusted at each site and phone visit if needed by the investigator . Follow-up occurred 7 and 30 days after end of treatment.

Standardized meal test
Participants had venous PPG levels assessed before and after a bolus dose of faster aspart or IAsp (0.1 U/kg, calculated by the investigator), which was followed by a standardized liquid meal (Ensure, Abbott Nutrition, Columbus, USA; 78 g carbohydrate consumed within 12 min). Only a standard wave bolus, where all bolus insulin is delivered at once, was allowed. Participants were required to attend the visit in a fasting state, with a self-measured blood glucose (SMBG) of 4.0–8.8 mmol/L (71–160 mg/dL). Changes to basal rate settings 0–4 h before the test were not allowed. Blood samples were taken immediately before as well as 30 min, and 1, 2, 3, and 4 h after the meal. The meal test was conducted with pre-trial insulin before randomization, and with participant’s study medication at week 16. 

Continuous glucose monitoring (CGM) 
No more than 50% of participants were allowed to use their own real-time CGM during the trial. Participants who did not use CGM pre-trial did not start using CGM after enrolment. Participants who were using CGM pre-trial did not change normal practice after enrolment. They were not allowed to use low glucose suspend mode if it was a pump feature. Randomization was stratified according to use of unblinded CGM. All participants were provided with a blinded CGM device to wear during three trial periods: 1) before randomization (including during the pre-treatment meal test); 2) before the 8th week after randomization; and 3) before the 16th week after randomization (including during the within-treatment meal test). 

Self-measured blood glucose (SMBG)




The primary endpoint was change from baseline in HbA​1c 16 weeks after randomization.

Secondary endpoints
Confirmatory secondary endpoints were change from baseline 16 weeks after randomization in: 1-h PPG increment (meal test), 1,5-anhydroglucitol (1,5-AG), and time spent in low interstitial glucose (IG; ≤3.9 mmoL/L [70 mg/dL]) during CGM. Supportive secondary endpoints are listed in Supplementary Table 1. 

Severe hypoglycaemia was defined according to the American Diabetes Association classification ADDIN EN.CITE 12 and BG-confirmed hypoglycaemia was defined as a plasma glucose value <3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Meal-related hypoglycaemic episodes were evaluated from start of meal [0–1, >1–2, >2–3 and >3–4 h time points]).

Statistical analysis
All statistical analyses were prespecified. Efficacy endpoints were summarized and analysed using the full analysis set and results are presented based on data from all randomized participants for the entire trial period, which includes data collected after participants prematurely discontinued treatment. Safety endpoints (and insulin dose and pump parameters) were summarized using the safety analysis set (participants who received ≥1 dose of IAsp or faster aspart) and are presented based on data collected up to and including 7 days after discontinuation of treatment. Statistical analysis of the primary and secondary confirmatory endpoints followed a stepwise hierarchical procedure (Supplementary Figure 2). Non-inferiority (primary endpoint) was confirmed if the upper boundary of the two-sided 95%CI was ≤0.4%. One-sided P‑values are presented for non-inferiority analyses and for the other confirmatory analyses, with two-sided P-values for treatment differences presented for all other analyses.

Change from baseline in HbA1c, PPG and PPG increment (meal test) 16 weeks after randomization was analysed using a multiple imputation model. HbA1c responder endpoints were analysed using a logistic regression model. Change from baseline in mean 7-7-9-point profiles, mean PPG, mean PPG increments (7-7-9-point profiles), 1,5-AG, time spent in low IG, mean prandial IG increments, FPG, and body weight were analysed using a multiple imputation model similar to the model used for the primary endpoint. The number of treatment-emergent severe or BG-confirmed hypoglycaemic episodes was analysed using a negative binomial regression model.

The sample-size calculation and further details on statistical methods for the primary and secondary endpoints are in the Supplementary Appendix.

Results
A total of 472 participants were randomized to CSII treatment with either faster aspart (n = 236) or IAsp (n = 236) between July 2016 and July 2017. All randomized participants were exposed to treatment; 463 (98.1%) participants completed the trial period while 455 (96.4%) completed the treatment period without premature discontinuation of randomized treatment (Supplementary Figure 3). The most frequent reason for discontinuing treatment or withdrawing from the trial was ‘participant decision’. Baseline characteristics were similar between treatment arms (Table 1). Approximately 25% of participants in each treatment arm were using their own CGM device. 

In both treatment arms, HbA1c changed from 7.80% to 7.49% during the run-in period, followed by a further change 16 weeks after randomization to 7.44% in the faster aspart arm, and 7.35% in the IAsp arm (Figure 1). Non-inferiority of faster aspart to IAsp in terms of change from baseline in HbA1c was confirmed with an estimated treatment difference (ETD [95%CI]) of 0.09% [0.01;0.17] (1.00 mmol/mol [0.14;1.87]; P < 0.001 for non-inferiority [0.4% margin]). This difference was statistically significantly in favour of IAsp (P < 0.02). Superiority of faster aspart to IAsp with regard to the change from baseline in HbA1c could not be confirmed. Therefore, the hierarchical testing was stopped after step 3 (Supplementary Table 2).

The proportion of participants achieving HbA1c target <7.0% (53 mmol/mol) is presented in Supplementary Table 3. The odds of achieving HbA1c <7.0% (53 mmol/mol) were not statistically significantly different between faster aspart and IAsp (ETD [95%CI] 0.76 [0.46;1.26]).

The observed change from baseline in 1-h PPG increment was –0.89 mmol/L (–16.0 mg/dL) and 0.05 mmol/L (0.98 mg/dL) in the faster aspart and IAsp arms, respectively (Figure 2). Superiority of faster aspart to IAsp in terms of change from baseline in 1-h PPG increment was confirmed (ETD [95%CI] –0.91 mmol/L [–1.43;–0.39]; –16.4 mg/dL [–25.7;–7.0], P = 0.001). The estimated change from baseline in 30-minute and 2-h PPG increment was also significantly in favour of faster aspart (30-minute: –0.66 mmol/L [–1.00;–0.31], –11.8 mg/dL [–18.1;–5.6], P < 0.001; 2-h: –0.90 mmol/L [–1.58;–0.22], –16.2 mg/dL [–28.5;–4.0], P = 0.01). There were no statistically significant differences at 3 h and 4 h (Figure 2). The ETD for the change from baseline in PPG was also statistically significant in favour of faster aspart at 30 min, 1 h and 2 h (Supplementary Table 3). IG measurements during the meal test also support the PPG findings above (Supplementary Table 3).

Prandial IG and IG increment profiles at baseline and week 16 are presented in Figure 3. For breakfast, lunch, main evening meal, and across all meals the incremental rise in mean IG after 30 min, 1 h and 2 h was lower with faster aspart vs IAsp, with statistically significant ETDs after 1 h and 2 h for each individual meal and the mean across all meals (Supplementary Figure 4). There was no statistically significant difference between treatments in the change from baseline to IG peak or time to IG peak (Supplementary Table 3). The mean time spent in low IG (≤3.9 mmol/L [70 mg/dL]) changed from 85.4 min/day and 79.9 min/day at baseline to 78.6 min/day and 83.0 min/day at week 16 with faster aspart and IAsp, respectively, with no statistical difference between treatments (ETD [95%CI] –6.74 min/day [–15.56;2.1]). At week 16, the percentage of time spent in low IG (≤3.9 mmol/L [70 mg/dL]) was 5.5% and 5.8%, and for IG in target range (4.0–10.0 mmol/L [71–180 mg/dL]) it was 52.4% and 54.5% with faster aspart and IAsp, respectively. The mean of the IG profile and the coefficient of variation in the IG profile were similar from baseline to 16 weeks for both treatments (Supplementary Table 3). The 24-h IG profiles at week 16 between faster aspart and IAsp were broadly comparable, although the median and interquartile range IG values during the night trended higher compared with baseline in the faster aspart group (Supplementary Figure 5).

The observed change from baseline in 1,5-AG 16 weeks after randomization was 0.14 μg/mL and 0.25 μg/mL in the faster aspart and IAsp arms, respectively, with no statistically significant difference between treatments (ETD [95%CI] –0.10 μg/mL [–0.36;0.17]).

The change from baseline in the estimated mean of the 7-7-9 SMBG profiles was not significantly different between treatments (Supplementary Figure 6, Supplementary Table 3). The observed change from baseline in the 1-h PPG increment, based on the 7-7-9 SMBG profiles, combined across all three main meals was –0.53 mmol/L (–9.60 mg/dL) with faster aspart and 0.12 mmol/L (2.12 mg/dL) with IAsp, with a statistically significant difference in favour of faster aspart (ETD [95%CI] –0.46 mmol/L [–0.90;–0.02]; –8.3 mg/dL [–16.3;–0.3]; P = 0.042). There were no significant differences in 1-h PPG increment (and 1-h PPG) at any individual meal (i.e. breakfast, lunch or at the main evening meal). 

In both treatment groups, mean FPG showed an increase from baseline until week 8 and thereafter a decrease until week 16, with no statistically significant difference between treatments (ETD [95%CI] –0.07 mmol/L [–0.50;0.36]; –1.29 mg/dL [–9.05;6.48]). The fasting SMBG levels on the days when the meal tests were performed had to be 4.0–8.8 mmol/L (71–160 mg/dL). At week 8 there was no requirement for any particular fasting SMBG value.

Mean and median daily basal and bolus insulin doses remained stable over the treatment period in both groups (Supplementary Table 4), with basal:bolus ratios of 48/52 at baseline and at week 16 of 48/52 and 49/51 with faster aspart and IAsp, respectively, at week 16 . The median insulin:carbohydrate ratio decreased with both treatments from 9.18 to 9.00 g/U with faster aspart and from 9.05 to 8.83 g/U with IAsp. Mean insulin sensitivity factor was 2.64 and 2.50 mmol/L/U at baseline, and 2.65 and 2.60 mmol/L/U 16 weeks after randomization with faster aspart and IAsp, respectively. Mean active insulin time was 3.6 h at baseline and week 16 for both treatment groups. 

The observed rates of treatment-emergent severe or BG-confirmed hypoglycaemia were 45.07 and 45.29 episodes per patient-year of exposure (PYE) with faster aspart and IAsp, respectively. The overall rate of treatment-emergent severe or BG-confirmed hypoglycaemic episodes was not statistically significantly different between treatments with an estimated rate ratio [95%CI] of 1.00 [0.85;1.16]. A higher rate of severe or BG-confirmed hypoglycaemic episodes was observed for faster aspart vs IAsp within the first hour after the start of a meal (1.25 vs 0.71 events/PYE; estimated rate ratio 95%CI 1.78 [1.15;2.75]), with no statistically significant differences at other intervals during the first 4 h after the start of the meal (Supplementary Table 5, Supplementary Figure 7). A numerically higher rate of severe hypoglycaemia was observed with faster aspart (0.29 events/PYE) vs IAsp (0.10 events/PYE) during the 16 weeks after randomization. During the run-in period, three participants who were later randomized to faster aspart reported a total of four severe hypoglycaemic episodes; these three participants also reported 10 of the 21 severe hypoglycaemic episodes reported with faster aspart during the treatment period. No severe hypoglycaemic episodes were reported during the run-in period by those participants later randomized to IAsp. 

The observed rate of unexplained hyperglycaemic episodes was 16.3 and 14.8 episodes/PYE with faster aspart and IAsp, respectively. The percentage of participants reporting TEAEs and the overall rate of TEAEs were similar between both treatment arms (Supplementary Table 6). The event rate for infusion-site reactions possibly or probably related to trial product was numerically higher with faster aspart (5.5% of participants [0.29 events/PYE]) vs IAsp (3.8% of participants [0.18 events/PYE]) (Supplementary Table 6). Allergic reactions were reported in 4.2% and 3.0% of participants with faster aspart and IAsp, respectively (0.14 vs 0.09 events/PYE). Most adverse events (AEs) were non-serious, of mild or moderate severity, and judged to be unlikely related to trial product. The mean body weight increase from baseline at week 16 was <1 kg in both treatment arms, with a statistically significant difference in favour of IAsp (ETD [95%CI] −0.43 kg [–0.81;–0.06]; P = 0.024). No clinically significant differences were seen from baseline to week 16 with regard to vital signs, physical examination, fundus photography/fundoscopy, laboratory assessments (biochemistry, haematology, lipids and urinalysis), and no relevant changes in electrocardiogram parameters were noted.

The mean number of infusion-set changes per week was similar in the faster aspart and IAsp groups (2.55 vs 2.49, respectively). A similar rate of non-routine infusion-set changes was reported with faster aspart and IAsp (6.97 vs 6.68 events), although a higher proportion of participants reported non-routine changes with faster aspart vs IAsp (71.2 vs 57.2%). Non-routine changes reported by participants to be caused by a perceived occlusion or unexplained hyperglycaemia were similar between treatment groups, while changes due to infusion-site reactions were numerically higher with faster aspart vs IAsp (Supplementary Table 7).

Discussion
In this randomized trial, faster aspart was shown to be effective in glycaemic control because non-inferiority to IAsp in CSII for the change from baseline in HbA1c after 16 weeks was achieved. Superiority of faster aspart over IAsp in the change in HbA1c, however, was not confirmed, with a small but statistically significant difference in favour of IAsp. Faster aspart significantly improved PPG increment vs IAsp at 30 min, 1 h (superiority confirmed) and 2 h after a standardized meal test, and this difference was supported by CGM IG postprandial increments and SMBG postprandial increments. These results align well with previous studies. ADDIN EN.CITE 10,13,14 However, in light of the positive PPG findings in the current trial, it is surprising that faster aspart did not improve HbA1c to a greater extent than IAsp, particularly because a statistically significant difference in favour of faster aspart was demonstrated in a previous study in people with T1D using MDI (onset 1). ADDIN EN.CITE 10 Contrasting the IG profiles for faster aspart and IAsp, the higher nocturnal and pre-meal levels of IG for participants receiving faster aspart may have countered the expected overall glycaemic benefit of improved PPG control. The reasons underlying this rise in IG are unclear. However, it is likely that both the basal rate and bolus pump settings used for this double-blinded trial required further optimization to adjust delivery according to the distinct pharmacological profile of faster aspart. Specific recommendations for the use of faster aspart in CSII may include a different distribution of insulin doses between basal and bolus.

The risk of overall severe or BG-confirmed hypoglycaemia was similar between treatment groups. However, the rate of severe or BG-confirmed hypoglycaemia for the small proportion of episodes reported 1 h after the meal was significantly higher with faster aspart vs IAsp (with no significant differences at other time intervals). This finding was also reported in the onset 1 study after 26 and 52 weeks. ADDIN EN.CITE 10,13 Collectively, these findings reflect the left-shifted time–action profile of faster aspart; ADDIN EN.CITE 4 that is, the increased early absorption, faster onset of action and greater early glucose-lowering effect (vs IAsp) that can lead to earlier onset of hypoglycaemia following a meal. During the 16 weeks following randomization, a numerical imbalance in severe hypoglycaemia was observed whereby a threefold increase in the number of events was reported with faster aspart vs IAsp (0.29 vs 0.10 events/PYE). This finding may be partly due to an imbalance when randomizing participants who had previously experienced severe hypoglycaemia during the run-in period. All three of these participants were randomly assigned to the faster aspart group and experienced 10 of the 21 episodes of severe hypoglycaemia during the treatment period. 

The overall safety profiles for faster aspart and IAsp in terms of AEs were broadly comparable and as expected for insulin aspart formulations. The rate of infusion-set changes (routine and non-routine) was similar between groups. A numerically higher number of infusion-site reactions (a cited reason for non-routine changes) was reported with faster aspart vs IAsp (0.29 vs 0.18 events/PYE, respectively). Further supporting the results of the onset 4 study,11 these findings indicate that faster aspart is safe to use and compatible with CSII. 

This trial is the first to evaluate the efficacy and safety of an ultra-fast-acting insulin in CSII therapy in a large number of participants (with a high participant retention rate) over a clinically meaningful treatment period. With the development of increasingly sophisticated insulin delivery systems comes the need for faster-acting, more physiological insulins that are better able to control PPG fluctuations. This trial showed that faster aspart provides an effective and safe option for CSII treatment in people with T1D, with improvements in PPG control reflected in meal-test and CGM results. 
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Figure 1. Mean HbA1c over time.
Error bars: ± standard error (mean).
*Estimated treatment difference was 0.09% [95%CI 0.01;0.17], P = 0.022, in favour of insulin aspart. Non-inferiority confirmed at 0.4% level (P-value from the one-sided test for non-inferiority evaluated at the 2.5% level: P < 0.001). 
All available information regardless of treatment discontinuation was used. 
Faster aspart, fast-acting insulin aspart.


Figure 2. PPG increment after a standardized meal test at baseline and week 16.
Error bars: ± standard error (mean).
*ETD [95%CI] at week 16: −0.66 mmol/L [−1.00;−0.31], −11.8 mg/dL [−18.1;−5.6], P < 0.001
**ETD [95%CI] at week 16: −0.91 mmol/L [−1.43;−0.39], −16.4 mg/dL [−25.7;−7.1], P = 0.001
***ETD [95%CI] at week 16: −0.90 mmol/L [−1.58;−0.22], −16.2 mg/dL [−28.5;−4.0], P = 0.01 
All available information regardless of treatment discontinuation was used.
ETD, estimated treatment difference; faster aspart, fast-acting insulin aspart; PPG, postprandial glucose.


Figure 3. Prandial interstitial glucose (IG) profiles. IG increment and IG at baseline (A, B) and week 16 (C, D).
Error bars: ± standard error (mean).
Prandial interstitial glucose increment is derived as the interstitial glucose values subtracted by the mean of interstitial glucose values within 15 min before the start of the meal. Meal times during the CGM period were captured in participant’s diaries.
All available information regardless of treatment discontinuation was used.





Table 1. Baseline characteristics
	Faster aspart 
(n = 236)	Insulin aspart
(n = 236)	Total(n = 472)
Age, years	43.3 (14.8)	43.6 (14.7)	43.5 (14.7)
Male, n (%)	103 (43.6)	100 (42.4)	203 (43.0)
Body weight, kg                       lb	76.9 (15.2)169.5 (33.5)	78.2 (14.5)172.4 (31.9)	77.5 (14.8)170.9 (32.7)
BMI, kg/m2	26.2 (4.1)	26.5 (3.9)	26.3 (4.0)
Duration of diabetes, years	25.0 (12.7)	23.3 (11.3)	24.2 (12.0)
HbA1c, %            mmol/mol	7.5 (0.5)58.4 (6.0)	7.5 (0.5)58.4 (5.8)	7.5 (0.5)58.4 (5.9)
FPG, mmol/L         mg/dL	7.6 (2.6)136.9 (47.6)	7.4 (2.3)133.3 (41.7)	7.5 (2.5)135.1 (44.7)
Previous insulin use, n (%)    Insulin aspart    Insulin lispro    Insulin glulisine	126 (53.4)102 (43.2)8 (3.4)	142 (60.2)86 (36.4)8 (3.4)	268 (56.8)188 (39.8)16 (3.4)
Pump model at screening (%)    Paradigm Veo†    Minimed 530G†    Paradigm    Paradigm Revel	132 (55.9)47 (19.9)35 (14.8)22 (9.3)	119 (50.4)49 (20.8)35 (14.8)33 (14.0)	251 (53.2)96 (20.3)70 (14.8)55 (11.7)
Infusion set first dispensed‡ (%)   Quick-set   Silhouette   Mio   Sure-T (Easy set)	154 (65.3)41 (17.4)24 (10.2)17 (7.2)	170 (72.0)35 (14.8)19 (8.1)12 (5.1)	324 (68.6)76 (16.1)43 (9.1)29 (6.1)
Data are mean (SD) unless otherwise stated.
†Low glucose suspend feature not allowed as per protocol. ‡Participants were free to change infusion sets during the trial. 
The recommended frequency for changing each infusion set was every 3 days for the Quick-set, Silhouette, and the Mio; and every 2 days for the Sure-T, as per the manufacturers’ recommendation. 
BMI, body mass index; faster aspart, fast-acting insulin aspart; FPG, fasting plasma glucose; SD, standard deviation.
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